Skip to Content
Merck
  • Transcriptome sequencing analysis of mono‑ADP‑ribosylation in colorectal cancer cells.

Transcriptome sequencing analysis of mono‑ADP‑ribosylation in colorectal cancer cells.

Oncology reports (2020-04-24)
Ning-Ning Zhang, Ting Lin, Ming Xiao, Qing-Shu Li, Xian Li, Lian Yang, Chuan-Ling Wang, Ya-Lan Wang
ABSTRACT

Colorectal cancer (CRC) is a global health concern. The role of epigenetics in tumors has garnered increasing interest. ADP ribosylation is an epigenetic modification that is associated with a variety of biological functions and diseases, and its association with tumor development and progression has been hypothesized. However, due to the limitations of available techniques and methods, ADP ribosylation of specific sites is difficult to determine. In previous studies, it was shown that arginine‑117 of histone 3 (H3R117) in Lovo cells can be modified by mono‑ADP‑ribosylation. This site was mutated and Lovo cells overexpressing this mutant construct were established. In the present study, the expression of differentially expressed genes (DEGs) between untransfected Lovo cells and H3R117A Lovo cells was analyzed. A total of 58,174 DEGs were identified, of which 2,324 were significantly differentially expressed (q‑value <0.05; fold change >2). Functional annotation and Kyoto Encyclopedia of Genes and Genomes pathway enrichment was used to analyze the functions and possible roles of the DEGs. The DEGs were enriched in pathways associated with metabolic process, catalytic activity, organelle and chromatin structure, and dynamics. Through this comprehensive and systematic analysis, the role of mono‑ADP‑ribosylation in CRC was examined, providing a foundation for future studies.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-mono- ADP-ribose binding reagent, from Escherichia coli